Ascent Therapeutics Raises $19 Million

Ascent Therapeutics Inc., a Cambridge, Mass.-based developer of GPCR modulators, has raised $19 million in Series A funding. Backers include Novartis Option Fund, Healthcare Ventures and TVM Capital. It also has filled out its senior management team, including CEO Frederick Jones (former head of Devgen NV’s pharma unit).

North AmericaUSBriefs